This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

The incidence of LON is higher in highly immunosuppressed patients, as seen in lymphoma patients ... IgM levels after rituximab treatment may help in risk scoring. The mechanisms of LON seem ...

FL with blastoid or large centrocyte cytologic features, or follicular large B-cell lymphoma (FL grade 3B) are excluded. Rituximab/hyaluronidase human is administered subcutaneously (first dose IV ...

“This elucidation of MIPLYFFA’s ® highly differentiated mechanism of action marks a critical step in understanding its interactions with Niemann-Pick disease type C (NPC) at a cellular level ...

Zevra Therapeutics, Inc. announced the publication of a study on arimoclomol, branded as MIPLYFFA, in the journal Molecular Genetics and Metabolism, highlighting its unique mechanism of action in ...

A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

See the top gainers, losers, invest and get updated what's happening in the crypto market ...